Engineered Probiotic Bacteria for PKU Phenylalanine Control
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current treatments for hyperphenylalaninemia, such as phenylketonuria (PKU), require strict dietary restrictions and costly cofactor therapies, which are difficult to adhere to and have significant side effects, while there is a need for a more effective and reliable method to control blood phenylalanine levels.
Innovation Solution
Genetically engineered bacteria that express phenylalanine ammonia lyase (PAL) and/or phenylalanine hydroxylase, capable of metabolizing phenylalanine to non-toxic levels in the gut, are introduced to reduce hyperphenylalaninemia, with features like auxotrophy and kill-switches for bio-safety.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If strict dietary restrictions and costly cofactor therapies are used to treat hyperphenylalaninemia, then blood phenylalanine levels can be controlled, but patient quality of life deteriorates due to difficulty in adherence and significant side effects
Solution Approach 1:
The patent introduces genetically engineered bacteria as an intermediary therapeutic agent that resides in the gastrointestinal tract and continuously metabolizes phenylalanine. These bacteria express phenylalanine ammonia lyase (PAL) and/or phenylalanine hydroxylase enzymes, serving as a living mediator that converts excess phenylalanine into non-toxic metabolites (trans-cinnamic acid and ammonia) in the gut, thereby providing reliable blood phenylalanine control without requiring strict dietary adherence from the patient
2Reliability
If genetically engineered bacteria expressing phenylalanine metabolizing enzymes are introduced, then a more effective and reliable treatment method is achieved, but new safety concerns and potential harmful effects are introduced
Solution Approach 1:
The patent incorporates multiple pre-designed safety mechanisms into the genetically engineered bacteria before administration. These include auxotrophic markers that prevent autonomous survival, kill-switch genetic circuits that can eliminate the bacteria if they persist too long or cause adverse effects, and carefully selected bacterial strains with reduced pathogenicity. These beforehand cushioning measures address bio-safety concerns proactively while maintaining treatment effectiveness
Solution Approach 2:
The patent modifies specific genetic parameters of the bacteria to achieve the desired therapeutic effect while controlling safety risks. By introducing specific genes (PAL and/or phenylalanine hydroxylase) at controlled expression levels, and by modifying bacterial metabolism through auxotrophic markers, the treatment effectiveness is enhanced while safety parameters are simultaneously optimized through the built-in containment mechanisms
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
The engineered bacteria effectively metabolize phenylalanine, reducing blood levels and allowing for a more natural diet, providing a stable and safe treatment option for PKU.
Implementation Method 1
bacteria are engineered to contain genes for the expression of anti-inflammatory agents or agents that aid in the healing of a disrupted gut-barrier, such as the short chain fatty acid butyrate
Implementation Method 2
bacteria have been genetically modified to treat phenylketonuria (PKU) by expressing one or more enzymes which metabolize phenylalanine and thereby consuming excess phenylalanine within the gastrointestinal tract
Data Source
AI summary
Modified probiotics, pharmaceutical compositions thereof, and methods of modulating and treating disorders are disclosed.